Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Thomasson, Marcus ^a   Hedman, Håkan ^a   Ljungberg, Börje ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

EGFR; ERBB2; ERBB3; ERRB4; LRIG1; Renal cell carcinoma; Survival

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; LRIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MULTIGENE FAMILY; PATHOLOGY; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; KIDNEY CORTEX; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIGENE FAMILY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RNA, MESSENGER;

EID: 84860374309     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-216     Document Type: Article

References (24)

1. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). S Störkel, J Eble, K Adlakha, M Amin, M Blute, D Bostwick, M Darson, B Delahunt, K Iczkowski, Cancer 1997 80 987 989 10.1002/(SICI)1097- 0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R 9307203
2. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. WM Linehan, J Vasselli, R Srinivasan, MM Walther, M Merino, P Choyke, C Vocke, L Schmidt, JS Isaacs, G Glenn, et al. Clin Cancer Res 2004 10 6282S 6289S 10.1158/1078-0432.CCR-050013 15448018 (Pubitemid 39287479)
3. Genetics and epigenetics of renal cell cancer. MM Baldewijns, IJ van Vlodrop, LJ Schouten, PM Soetekouw, AP de Bruine, M van Engeland, Biochim Biophys Acta 2008 1785 133 155 18187049
4. Untangling the ErbB signalling network. Y Yarden, M Sliwkowski, Nat Rev Mol Cell Biol 2001 2 127 137 10.1038/35052073 11252954 (Pubitemid 33674041)
5. The ErbB signaling network: receptor heterodimerization in development and cancer. M Olayioye, R Neve, H Lane, N Hynes, EMBO J 2000 19 3159 3167 10.1093/emboj/19.13.3159 10880430 (Pubitemid 30428195)
6. Cloning, characterization, and expression of human LIG1. J Nilsson, C Vallbo, D Guo, I Golovleva, B Hallberg, R Henriksson, H Hedman, Biochem Biophys Res Commun 2001 284 1155 1161 10.1006/bbrc.2001.5092 11414704 (Pubitemid 32917959)
7. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. G Gur, C Rubin, M Katz, I Amit, A Citri, J Nilsson, N Amariglio, R Henriksson, G Rechavi, H Hedman, et al. EMBO J 2004 23 3270 3281 10.1038/sj.emboj.7600342 15282549 (Pubitemid 39209151)
8. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. MB Laederich, M Funes-Duran, L Yen, E Ingalla, X Wu, KL Carraway, C Sweeney, J Biol Chem 2004 279 47050 47056 10.1074/jbc.M409703200 15345710 (Pubitemid 39518360)
9. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. S Goldoni, RA Iozzo, P Kay, S Campbell, A McQuillan, C Agnew, JX Zhu, DR Keene, CC Reed, RV Iozzo, Oncogene 2007 26 368 381 10.1038/sj.onc.1209803 16847455 (Pubitemid 46122827)
10. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. W Yi, C Holmlund, J Nilsson, S Inui, T Lei, S Itami, R Henriksson, H Hedman, Exp Cell Res 2011 317 504 512 10.1016/j.yexcr.2010.11.005 21087604
11. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. DL Shattuck, JK Miller, M Laederich, M Funes, H Petersen, KL Carraway, C Sweeney, Mol Cell Biol 2007 27 1934 1946 10.1128/MCB.00757-06 17178829
12. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. F Ledda, O Bieraugel, SS Fard, M Vilar, G Paratcha, J Neurosci 2008 28 39 49 10.1523/JNEUROSCI.2196-07.2008 18171921
13. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. JK Miller, DL Shattuck, EQ Ingalla, L Yen, AD Borowsky, LJ Young, RD Cardiff, KL Carraway, C Sweeney, Cancer Res 2008 68 8286 8294 10.1158/0008-5472.CAN-07-6316 18922900
14. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? H Hedman, J Nilsson, D Guo, R Henriksson, Acta Oncol 2002 41 352 354 10.1080/ 028418602760169398 12234026
15. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. A Tanemura, T Nagasawa, S Inui, S Itami, Dermatol Surg 2005 31 423 430 15871317 (Pubitemid 40489303)
16. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. AK Lindstrom, K Ekman, U Stendahl, T Tot, R Henriksson, H Hedman, D Hellberg, Int J Gynecol Cancer 2008 18 312 317 10.1111/j.1525-1438.2007.01021.x 17624990 (Pubitemid 351365217)
17. Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ER{alpha}-Positive Breast Cancer. SR Krig, S Frietze, C Simion, JK Miller, WH Fry, H Rafidi, L Kotelawala, L Qi, OL Griffith, JW Gray, et al. Mol Cancer Res 2011 9 1406 1417 10.1158/1541-7786.MCR-11-0227 21821674
18. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: A quantitative RT-PCR and immunohistochemical analysis. M Thomasson, H Hedman, D Guo, B Ljungberg, R Henriksson, Br J Cancer 2003 89 1285 1289 10.1038/sj.bjc.6601208 14520461 (Pubitemid 37363418)
19. ErbB4 is downregulated in renal cell carcinoma-a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. M Thomasson, H Hedman, TT Junttila, K Elenius, B Ljungberg, R Henriksson, Acta Oncol 2004 43 453 459 10.1080/02841860410028574 15360049 (Pubitemid 39037093)
20. Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. G Hofmockel, S Riess, I Bassukas, J Dammrich, Eur Urol 1997 31 478 484 9187911 (Pubitemid 27234641)
21. Epidermal growth factor binding by membranes of human renal cell carcinomas: establishment of an epidermal growth factor receptor assay for clinical use. K Yoshida, A Tosaka, Int J Urol 1994 1 319 323 10.1111/j.1442-2042.1994.tb00057.x 7614394
22. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. D Lager, D Slagel, P Palechek, Mod Pathol 1994 7 544 548 7937720
23. Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy. B Ljungberg, M Gafvels, J Damber, Urol Res 1994 22 305 308 10.1007/BF00297200 7879316 (Pubitemid 24369386)
24. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. T Sakaeda, N Okamura, A Gotoh, T Shirakawa, S Terao, M Morioka, K Tokui, H Tanaka, T Nakamura, M Yagi, et al. Pharm Res 2005 22 1757 1761 10.1007/s11095-005-7094-2 16180134 (Pubitemid 41355916)